

# *DATA, DECISION-MAKING AND DEVELOPMENT*

**Chand Mehta**  
**Beth Evans**



## Topics for today


**Data for decision-making – new data source**

Innovative vaccine development – survey responses

Questions


## Earlier this year we discussed ‘data for decision making’

We asked you how often someone in your company uses the following publicly available data sources:



# We're now excited to bring you the Global Vaccine Market Model (GVMM), free to use for DCVMs (1/2)

CHAI and Linksbridge want to share this continuously updated vaccine demand and supply data, that you can query, analyze and download as proper data sets




1. Data offered is subset of **Global Vaccine Market Model (GVMM)**, already available and used by vaccine partners
2. Data is **user friendly** and is presented as tabulated information (rather than predefined)
3. Suppliers can **query data online and carry out own analyses** using Tableau Server functionality
4. Or, **download** to analyze in companies' own preferred tool

# We're now excited to bring you the Global Vaccine Market Model (GVMM), free to use for DCVMs (2/2)

## What data can you expect in GVMM?

### Module #1: Countries

Current and projected country income and Gavi eligibility status through 2030



**Contents:**

- UNPD estimated birth cohort
- IMF projected GDP per capita
- Gavi co-financing status
- For all countries in the world
- By WHO region, World Bank status, and Gavi eligibility

**Notes:**


- Updated for users—so they don't have to
- Includes Gavi board decision monitoring etc. for changes to status policies
- Public and privileged source data only

© 2020 Linksbridge SPC | 7

Level 1	▪ Global demand data by WB income group	▪ No requirement
---------	---	------------------

### Module #2: Demand

Demand for all vaccines for all countries 2000–2030, and partial information on campaign, outbreak and stockpile vaccines



**Contents:**

- Global public demand for vaccines for the period 2000 through 2030
- Includes known new vaccine introductions and product replacements—does not future vaccines e.g., GBS, malaria, second-generation dengue, RSV etc.

**Notes:**

- Combines data from:
  - WHO/UNICEF JRF
  - M4A Vaccine Purchase Data
  - Gavi SDFs
  - UNPD WPP
- Private market demand coming in January 2020 (estimated)

© 2020 Linksbridge SPC | 8

Level 2	▪ Global demand data by country ▪ Market value by product by WB income group	▪ Validate pipeline and marketed products
---------	---	---

## What's next?

- Are you interested in getting access to this free data set?
  - Please send an email to [gvm@linksbridge.com](mailto:gvm@linksbridge.com)
- We will reply within 24 hours with login details. After a week or so to explore the data, you'll receive a follow up email to see:
  - How helpful have you found the resources so far?
  - What additional information would be valuable to you?
- We remain open to your feedback at any point

## Topics for today

Data for decision-making – new data source

**Innovative vaccine development – survey responses**

Questions

## DCVMs have become key suppliers and developers for low- and middle-income countries


### Supply

DCVMs now supply vaccines for **~84% of the world's birth cohort** annually and **64/147 WHO-prequalified vaccines** are manufactured by DCVMs

*Peter Dull,  
Bill & Melinda Gates Foundation*



### Development



DCVMs have a **clear role in vaccine development and vaccine access in low- and middle-income countries** including, increasingly, for innovative vaccines


CHAI is interested in supporting **continued growth in vaccine development and access**

Source: [Dull et al., \(2019\)](#) , [McKinsey – Refueling the Innovation Engine in Vaccines \(2019\)](#)





Through the DCVMN Innovation Survey and follow-up conversations with partners, donors and developers, we have identified a few sets of challenges and potential solutions to explore further



## Topics for today

Data for decision-making – new data source

Innovative vaccine development – survey responses

**Questions**